Literature DB >> 26205535

Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.

Jessica Mandrioli1, Sara Biguzzi2, Carlo Guidi3, Elisabetta Sette4, Emilio Terlizzi5, Alessandro Ravasio6, Mario Casmiro7, Fabrizio Salvi8, Rocco Liguori9, Romana Rizzi10, Vladimiro Pietrini11, Annamaria Borghi12, Rita Rinaldi13, Nicola Fini14, Elisabetta Chierici15, Mario Santangelo16, Enrico Granieri17, Vittoria Mussuto18, Silvia De Pasqua9, Eleni Georgoulopoulou14, Antonio Fasano19, Salvatore Ferro20, Roberto D'Alessandro21.   

Abstract

Very few studies examined trend over time of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) and factors influencing it; previous studies, then, included only patients attending tertiary ALS Centres. We studied ALSFRS-R decline, factors influencing this trend and survival in a population-based setting. From 2009 onwards, a prospective registry records all incident ALS cases among residents in Emilia Romagna (population: 4.4 million). For each patient, demographic and clinical details (including ALSFRS-R) are collected by caring physicians at each follow-up. Analysis was performed on 402 incident cases (1279 ALSFRS-R assessments). The average decline of the ALSFRS-R was 0.60 points/month during the first year after diagnosis and 0.34 points/month in the second year. ALSFRS-R decline was heterogeneous among subgroups. Repeated measures mixed model showed that ALSFRS-R score decline was influenced by age at onset (p < 0.01), phenotype (p = 0.01), body mass index (BMI) (p < 0.01), progression rate at diagnosis (ΔFS) (p < 0.01), El Escorial Criteria-Revised (p < 0.01), and FVC% at diagnosis (p < 0.01). Among these factors, at multivariate analysis, only age, site of onset and ΔFS independently influenced survival. In this first population-based study on ALSFRS-R trend, we confirm that ALSFRS-R decline is not homogeneous among ALS patients and during the disease. Factors influencing ALSFRS-R decline may not match with those affecting survival. These disease modifiers should be taken into consideration for trials design and in clinical practice during discussions with patients on prognosis.

Entities:  

Keywords:  ALSFRS-R; Amyotrophic lateral sclerosis; Disease progression; Heterogeneity; Population-based study

Mesh:

Year:  2015        PMID: 26205535     DOI: 10.1007/s10072-015-2343-6

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  23 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

2.  Progression in ALS is not linear but is curvilinear.

Authors:  Paul H Gordon; Bin Cheng; Francois Salachas; Pierre-Francois Pradat; Gaelle Bruneteau; Philippe Corcia; Lucette Lacomblez; Vincent Meininger
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

Review 3.  Prognostic factors for the course of functional status of patients with ALS: a systematic review.

Authors:  Huub Creemers; Hepke Grupstra; Frans Nollet; Leonard H van den Berg; Anita Beelen
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

4.  Late-onset patients with sporadic amyotrophic lateral sclerosis in Japan have a higher progression rate of ALSFRS-R at the time of diagnosis.

Authors:  Yuji Tanaka; Nobuaki Yoshikura; Naoko Harada; Megumi Yamada; Akihiro Koumura; Takeo Sakurai; Yuichi Hayashi; Akio Kimura; Isao Hozumi; Takashi Inuzuka
Journal:  Intern Med       Date:  2012-03-15       Impact factor: 1.271

5.  Epidemiology of amyotrophic lateral sclerosis in Emilia Romagna Region (Italy): A population based study.

Authors:  Jessica Mandrioli; Sara Biguzzi; Carlo Guidi; Elisabetta Venturini; Elisabetta Sette; Emilio Terlizzi; Alessandro Ravasio; Mario Casmiro; Fabrizio Salvi; Rocco Liguori; Romana Rizzi; Vladimiro Pietrini; Elisabetta Chierici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Annamaria Borghi; Rita Rinaldi; Nicola Fini; Eleni Georgoulopoulou; Silvia De Pasqua; Marco Vinceti; Francesca Bonvicini; Salvatore Ferro; Roberto D'Alessandro
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-07       Impact factor: 4.092

6.  Amyotrophic lateral sclerosis disease progression model.

Authors:  Roberto Gomeni; Maurizio Fava
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-09-26       Impact factor: 4.092

7.  Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.

Authors:  Hazuki Watanabe; Naoki Atsuta; Ryoichi Nakamura; Akihiro Hirakawa; Hirohisa Watanabe; Mizuki Ito; Jo Senda; Masahisa Katsuno; Yuishin Izumi; Mitsuya Morita; Hiroyuki Tomiyama; Akira Taniguchi; Ikuko Aiba; Koji Abe; Kouichi Mizoguchi; Masaya Oda; Osamu Kano; Koichi Okamoto; Satoshi Kuwabara; Kazuko Hasegawa; Takashi Imai; Masashi Aoki; Shoji Tsuji; Imaharu Nakano; Ryuji Kaji; Gen Sobue
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-12-30       Impact factor: 4.092

8.  The ALSFRSr predicts survival time in an ALS clinic population.

Authors:  P Kaufmann; G Levy; J L P Thompson; M L Delbene; V Battista; P H Gordon; L P Rowland; B Levin; H Mitsumoto
Journal:  Neurology       Date:  2005-01-11       Impact factor: 9.910

9.  Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial.

Authors:  Petra Kaufmann; Gilbero Levy; Jacquelina Montes; Richard Buchsbaum; Alexandra I Barsdorf; Vanessa Battista; Rachel Arbing; Paul H Gordon; Hiroshi Mitsumoto; Bruce Levin; John L P Thompson
Journal:  Amyotroph Lateral Scler       Date:  2007-02

10.  Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis.

Authors:  Franco Franchignoni; Gabriele Mora; Andrea Giordano; Paolo Volanti; Adriano Chiò
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-20       Impact factor: 10.154

View more
  16 in total

1.  Advances in clinical neurology through the journal "Neurological Sciences" (2015-2016).

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2017-01       Impact factor: 3.307

2.  Stratification of ALS patients' survival: a population-based study.

Authors:  Benoît Marin; Philippe Couratier; Simona Arcuti; Massimiliano Copetti; Andrea Fontana; Marie Nicol; Marie Raymondeau; Giancarlo Logroscino; Pierre Marie Preux
Journal:  J Neurol       Date:  2015-10-30       Impact factor: 4.849

3.  Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis.

Authors:  Jessica Mandrioli; Edoardo Rosi; Nicola Fini; Antonio Fasano; Silvia Raggi; Anna Laura Fantuzzi; Giorgio Bedogni
Journal:  Neurol Sci       Date:  2017-10-04       Impact factor: 3.307

4.  The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset.

Authors:  Malcolm Proudfoot; Ashley Jones; Kevin Talbot; Ammar Al-Chalabi; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-02-11       Impact factor: 4.092

5.  Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model.

Authors:  Leonhard A Bakker; Carin D Schröder; Michael A van Es; Paul Westers; Johanna M A Visser-Meily; Leonard H van den Berg
Journal:  J Neurol       Date:  2017-06-12       Impact factor: 4.849

6.  Patients with ALS show highly correlated progression rates in left and right limb muscles.

Authors:  David J Rushton; Patricia L Andres; Peggy Allred; Robert H Baloh; Clive N Svendsen
Journal:  Neurology       Date:  2017-06-09       Impact factor: 9.910

7.  Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression.

Authors:  Alex G Karanevich; Jeffrey M Statland; Byron J Gajewski; Jianghua He
Journal:  BMC Med Res Methodol       Date:  2018-02-06       Impact factor: 4.615

8.  Imaging muscle as a potential biomarker of denervation in motor neuron disease.

Authors:  Thomas M Jenkins; James J P Alix; Charlotte David; Eilish Pearson; D Ganesh Rao; Nigel Hoggard; Eoghan O'Brien; Kathleen Baster; Michael Bradburn; Julia Bigley; Christopher J McDermott; Iain D Wilkinson; Pamela J Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-31       Impact factor: 10.154

9.  Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.

Authors:  Ruojie He; Minying Zheng; Ling Lian; Xiaoli Yao
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

10.  Unraveling the Complexity of Amyotrophic Lateral Sclerosis Survival Prediction.

Authors:  Stephen R Pfohl; Renaid B Kim; Grant S Coan; Cassie S Mitchell
Journal:  Front Neuroinform       Date:  2018-06-14       Impact factor: 4.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.